86.30
—
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Quest Laboratories
Its shares trade on NSE under the ticker QUESTLAB.NS. It has been listed since 23 May 2024. In the fiscal year to 31 March 2025, it reported revenue of ₹1.04bn and net income of ₹135.7m. At that date it held total assets of ₹1.22bn and shareholders' equity of ₹818.0m.
Quest Laboratories Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Dhar, Madhya Pradesh. The company went IPO on 2024-05-23. Quest Laboratories Limited is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. The firm produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms, such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. The tablets include Cetirizine Hydrochloride Tablet IP 10 mg, Zinc Sulphate Dispersible Tablet IP, Diclofenac Sodium Tablet BP, and others. The company offers dry syrup and suspension, such as Ferrous Sulphate & Folic Acid Syrup, Albendazole Suspension IP, Zinc Oral Solution USP, Alpha Amilase & Pepsine, Sucralfate Suspension, and others. Its ointments include Silver Sulphadiazine Cream IP, Diclofenac Diethylamino IP Gel, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 May 2024
- Website
- questlabltd.com ↗
Leadership
Pay as last reported
- Shri. Anil SabarwalExecutive Chairman of the Board, Managing Director, since 1998₹6.0m
- Shri. Ramkrishna SharmaChief Financial Officer₹660,000
- Smt. Tejaswini SabarwalWhole Time Director, since 2021₹1.5m
- Shri. Vinayak SabarwalExecutive Director
- Shri. Umendra SinghExecutive Director
- Shri. Amit ChandakNon-Executive Independent Director
- Shri. Gautam KothariNon-Executive Independent Director
- Shri. Basant MenghwaniNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Quest Laboratories manufactures a broad spectrum of pharmaceutical formulations including antibiotics and antimalarials.
- The firm produces ethical drugs, generic drugs, and over-the-counter drugs for diverse markets.
- Tablets like Cetirizine Hydrochloride and Zinc Sulphate Dispersible Tablet IP are key products.
Weaknesses
- The company is headquartered in Dhar, Madhya Pradesh, which may limit local talent access.
- Quest Laboratories Limited went IPO on 23 May 2024, indicating a recent market entry.
- Operating in the Health Care sector requires strict compliance with regulatory standards.
Opportunities
- Expanding the range of diabetes treatments and antidepressants can capture new patient segments.
- Offering oral dry powders and oral powders (ORS) addresses hydration needs in emerging markets.
- Producing Silver Sulphadiazine Cream IP and Diclofenac Diethylamino IP Gel meets specific medical demands.
Threats
- Intense competition in the Pharmaceuticals industry may pressure profit margins for generic drugs.
- Regulatory changes in India could impact the manufacturing of ethical drugs and OTC products.
- Supply chain disruptions might affect the production of Ferrous Sulphate & Folic Acid Syrup.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.